𝔖 Bobbio Scriptorium
✦   LIBER   ✦

DNA Repair capacity and cisplatin sensitivity of human testis tumour cells

✍ Scribed by Beate Köberle; Keith A. Grimaldi; Andrew Sunters; John A. Hartley; Lloyd R. Kelland; John R.W. Masters

Publisher
John Wiley and Sons
Year
1997
Tongue
French
Weight
96 KB
Volume
70
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Metastatic testicular germ cell tumours can be cured using cisplatin-based combination chemotherapy. To investigate the role of DNA repair in cisplatin sensitivity, we measured the formation and removal of cisplatin adducts in the whole genome and in specific genomic regions in 3 testis and 3 bladder cancer cell lines. Following a 1 hr exposure to 50 µM cisplatin, the mean level of DNA platination was lower in the testis tumour cell lines. During a 72 hr post-treatment incubation period, the 3 bladder cell lines removed platinum from the overall genome, whereas 2 of the testis tumour cell lines showed relatively little reduction of DNA platination. The third testis tumour cell line, SuSa, showed an intermediate capacity to remove cisplatin. Cisplatin-induced damage and repair in selected regions of the actively transcribed N-ras gene and the inactive CD3d gene were measured using quantitative PCR. The data were in agreement with those obtained with atomic absorption spectroscopy for the whole genome, showing that the bladder lines were repair-proficient: 2 of the testis tumour cell lines showed no repair, and the third testis line, SuSa, showed an intermediate level of repair in these 2 genes. Our findings confirm that reduced capacity to repair cisplatin-damaged DNA may contribute to the hypersensitivity of testis tumour cells to DNA-damaging agents.

📜 SIMILAR VOLUMES

Genetic basis of drug sensitivity in hum
Genetic basis of drug sensitivity in human testis tumour cells
✍ Xianghong Wang; Majid Hafezparast; John R. W. Masters 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 616 KB

Testicular germ cell tumoun (TGCT) are cured in over 80% of patients by using combination chemotherapy. However, the mechanism regulating this sensitivity has not been defined. Because cells derived from patients with DNA repair syndromes are similar to TCGT in their sensitivity to certain DNA-damag

Temperature-sensitive DNA repair of ultr
Temperature-sensitive DNA repair of ultraviolet damage in human cell lines
✍ Patricia Goss; P. G. Parsons 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 French ⚖ 672 KB

## Abstract Following exposure to ultraviolet irradiation (UV), two of three human fibroblast strains and one of three melanoma cell lines showed lower rates of thymine dimer excision during 24 h at 40° C than at 36° C. All lines had lower rates at 32° C. Autoradiographic studies of three fibroblas

Smoking, DNA repair capacity and risk of
Smoking, DNA repair capacity and risk of nonsmall cell lung cancer
✍ Hongbing Shen; Margaret R. Spitz; Yawei Qiao; Zhaozheng Guo; Li-E Wang; Carol H. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 83 KB 👁 1 views

## Abstract Tobacco‐related carcinogens cause a variety of DNA damage that is repaired by different enzymatic pathways, suggesting that DNA repair plays an important role in tobacco‐induced carcinogenesis. In a large hospital‐based case‐control study, we investigated DNA repair capacity (DRC) as a

v-src induces cisplatin resistance by in
v-src induces cisplatin resistance by increasing the repair of cisplatin–DNA interstrand cross-links in human gallbladder adenocarcinoma cells
✍ Naoko Masumoto; Shuji Nakano; Hiromitsu Fujishima; Kimitoshi Kohno; Yoshiyuki Ni 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 133 KB 👁 1 views

Activation of Src, which has an intrinsic protein tyrosine kinase (PTK) activity, has been demonstrated in human solid tumors, such as colorectal and breast cancers. To investigate the role of activated Src in drug resistance, we evaluated the effect of v-src on the resistance to various anti-cancer

Repair of cisplatin-DNA adducts by prote
Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma
✍ Sandra L. Jones; Ian D. Hickson; Adrian L. Harris; Paul R. Harnett 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 678 KB

## Abstract Human ovarian carcinoma exhibits a spectrum of responses to treatment with cisplatin, ranging from marked sensitivity to relative resistance. Variations in the efficiency with which cells repair cisplatin‐DNA adducts may in part determine cisplatin sensitivity. We have investigated the